Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;1(4):357-66.
doi: 10.2147/ciia.2006.1.4.357.

Candesartan in heart failure

Toni L Ripley  1 , Jennifer S Chonlahan, Robin E Germany
Affiliations
Review

Candesartan in heart failure

Toni L Ripley et al. Clin Interv Aging. 2006.

Abstract

Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1. It is a prodrug that is converted to its active metabolite during its variable absorption. It is highly protein bound with a small volume of distribution and a nine-hour half-life. Candesartan is one of two angiotensin receptor blockers approved for use in heart failure. MEDLINE was searched using OVID and PubMed to evaluate the evidence for using candesartan in patients with heart failure. Pharmacologic and pharmacokinetic evaluations, as well as clinical trials, were selected and are presented in this review. Clinical evidence supports the indication for use in systolic heart failure. Results for use in patients with diastolic heart failure were non-significant. Candesartan was well tolerated in the trials, with hyperkalemia, renal dysfunction, and hypotension being the most common adverse events. Use of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors needs further study; however, candesartan appears to provide added benefit in this setting. Candesartan is a safe and effective option for patients with systolic heart failure. Data regarding other angiotensin receptor blockers is underway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CHARM protocol and outcomes.
See this image and copyright information in PMC

References

    1. Adams KF, Lindenfeld J, Arnold JMO, et al. Executive Summary: HFSA 2006 Comprehensive heart failure practice guideline. J Cardiac Failure. 2006;12:10–38. - PubMed
    1. Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med. 2002;3(suppl 4):S3–9. - PubMed
    1. [ACC–AHA] American College of Cardiology–American Heart Association Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation. 2005;112:1825–52. - PubMed
    1. [AHA] American Heart Association . Dallas: AHA; 2006. Heart disease and stroke statistics – 2006 update.
    1. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J. 1999;20:1182–90. - PubMed

MeSH terms